医学
中止
阿达木单抗
依那西普
类风湿性关节炎
内科学
不利影响
回顾性队列研究
相伴的
比例危险模型
队列
药品
药理学
作者
K. Velthuis,Naomi T Jessurun,Thi D.M. Nguyen,Joep Scholl,Jurriaan R.G. Jansen,Jette A. van Lint,L. Kosse,Peter M. ten Klooster,Harald E. Vonkeman
标识
DOI:10.1080/14740338.2023.2172157
摘要
Background This study aims to compare nature and frequency of adverse drug reactions (ADRs), time to first ADR, drug survival, and the share of ADRs in treatment discontinuation of first-time treatment with adalimumab (ADA) and etanercept (ETN) in real-world RA patients.Research design and methods Retrospective, single-center cohort study including naïve patients treated between January 2003-April 2020. Time to first ADR and drug survival of first-time treatment were studied using Kaplan–Meier and Cox-regression models up to 10 years, with 2- and 5-year post-hoc sensitivity analysis. Nature and frequencies of first-time ADRs and causes of treatment discontinuation were assessed.Results In total, 416 patients (ADA: 255, ETN: 161, 4865 patient years) were included, of which 92 (22.1%) experienced ADR(s) (ADA: 59, 23.1%; ETN: 33, 20.4%). Adjusted for age, gender and concomitant conventional DMARD use, ADA was more likely to be discontinued than ETN up to 2-, 5- and 10-year follow-up (adjusted HRs 1.63; 1.62; 1.59 (all p<0.001)). ADRs were the second reason of treatment discontinuation (ADA 20.7%, ETN 21.4%).Conclusions Despite seemingly different nature and frequencies, ADRs are the second reason of treatment discontinuation for both bDMARDs. Furthermore, 2-, 5-, and 10-year drug survival is longer for ETN compared to ADA.
科研通智能强力驱动
Strongly Powered by AbleSci AI